New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 4, 2012
07:06 EDTCDXS, RGDXCodexis appoints David O’Toole as CFO
Codexis (CDXS) announced the appointment of David O’Toole as Senior Vice President and Chief Financial Officer, effective September 4. O’Toole served most recently as Vice President and Chief Financial Officer at Response Genetics, Inc. (RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer and analytical testing services of clinical trial specimens for the pharmaceutical industry.
News For CDXS;RGDX From The Last 14 Days
Check below for free stories on CDXS;RGDX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
13:19 EDTRGDXResponse Genetics to serve as molecular screening center for ALCHEMIST
Response Genetics (RGDX) announced that it has been awarded a multi-million dollar research subcontract to support the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials, or ALCHEMIST. ALCHEMIST consists of 3 integrated precision medicine trials that are being implemented through the National Clinical Trials Network of the National Cancer Institute, or NCI, a screening trial and two associated treatment trials. The research subcontract was awarded by Leidos Biomedical Research (LDOS).
August 14, 2014
07:16 EDTRGDXResponse Genetics expects FY14 to be 'transformational year'
The company said, "We expect FY14 could be a transformational year for our company in many respects, not the least of which is we expect both ResponseDX unit volumes and revenue to continue to increase as a result of the initiatives and infrastructure that we implemented over the last two years, including our TC/PC program, our recently acquired and launched ResponseDX: Tissue of OriginTM test, the introduction of several new tests and our where-with-all to provide unique testing services resulting from our patient-centric, multiple technology approach for providing pathologists and oncologists with testing options that they deem best suited for each of their patients based on individual patient needs. With these offerings in place, and our emphasis on execution, we believe we have strengthened our position as a content driven, solid tumor, molecular diagnostics company with a differentiated approach for today's rapidly changing and increasing cost conscious healthcare environment."
07:09 EDTRGDXResponse Genetics reports Q2 EPS (8c) vs. (4c) last year
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use